GreenLight Biosciences Holdings
GRNA
NASDAQ Global Market0.30
USD
+0.00
- -
GreenLight Biosciences Holdings
GRNA
(NASDAQ Global Market)
Recent
price
0.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- GreenLight Biosciences Holdings PBC (GRNA) is a pre-commercial stage biotechnology company that develops and commercializes RNA-based products for plant health, animal health, and human health applications using a proprietary cell-free ribonucleic acid (RNA) production platform. The company's core offerings include plant protection solutions such as Calantha, a dsRNA-based insecticide targeting the Colorado potato beetle; Norroa, the first RNA-based treatment launched in September 2025 for varroa mites affecting honeybees; programs against vegetable caterpillar complex (Diamondback moth), two-spotted spider mite complex (Tetranychus urticae), grape powdery mildew (for which a regulatory dossier was submitted in the US, EU, and Brazil in October 2025), botrytis cinerea (gray mold), fusarium head blight, and other fungal diseases including powdery mildew, downy mildew, Asian soybean rust, and rice blast; as well as breakthrough RNA herbicide development announced in April 2025. In human health, it advances mRNA vaccines and therapeutics, including preclinical candidates for COVID-19, shingles, oncology, and gene therapies for sickle cell disease and HIV suppression; prior partnerships encompass exclusive collaborations with Epivax Therapeutics for cancer vaccines, Serum Institute of India for up to five mRNA products targeting emerging markets in Africa, Latin America, the Middle East, and Asia, and Samsung Biologics for large-scale mRNA vaccine production. Founded in 2008 and headquartered in Medford, Massachusetts, the company operates primarily in the United States with recent expansions into Mexico, Brazil, and a Spanish subsidiary supported by €35 million from the European Investment Bank in June 2024 and EU grants; it went public in late 2022 via a merger with Environmental Impact Acquisition Corp. and announced additional financing in March 2025, alongside a USDA NIFA SBIR grant for soybean protection. GreenLight Biosciences targets farmers, beekeepers, and growers in the $79 billion crop protection market, as well as human health sectors, emphasizing sustainable, non-chemical alternatives to traditional pesticides and therapies.
GreenLight Announces Completion of Merger with Fall Line Endurance Fund
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
Why Greenlight Biosciences Stock Was in the Red Today
GreenLight Biosciences to cut 25% of its workforce as part of ‘realignment' to extend cash runway
Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
Why GreenLight Biosciences Stock Is Crushing It Today